Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIFF 3-Week Aptar Device Study
NCT05006599Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of regular human insulin in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Wake Forest University Health Sciences. Planned start May 2025; status: withdrawn.
02
Drugs
regular human insulin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05006599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006599.